NASDAQ$WHWK
Whitehawk Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Aadi Bioscience reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
Aadi Bioscience reported a net loss attributable to common stockholders of $16.0 million for the fourth quarter of 2021, compared to a net income of $7.8 million in the prior year quarter. As of December 31, 2021, cash and cash equivalents totaled $149.0 million. FYARRO was approved by the FDA on November 22, 2021, and launched in February 2022.
- FYARRO was approved on November 22, 2021 and launched on February 23, 2022.
- FYARRO added to NCCN® Guidelines as the only preferred therapy to treat malignant PEComa.
- PRECISION 1 tumor agnostic study for TSC1 or TSC2 alterations open for enrollment.
- Ended fourth quarter 2021 with $149.0 million in cash and cash equivalents.
Headline financials
Revenue & EPS history
Aadi Bioscience · Revenue · Quarterly
$1M
Revenue by segment
Aadi Bioscience · $5.96M total across 1 segment · Q3 2023
- Product Sales, Net$5.96M—100.0%
Forward guidance
Based on current plans, Aadi Bioscience expects cash and cash equivalents to fund operations into 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.8%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+4.1%
Avg return
30 days after
37%
11 / 30 earnings
Positive
+69.8%
Q1 2021
Best reaction
-18.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | -5.5% | -0.7% | |
| Q3 2025 | -0.4% | -3.5% | +10.2% | |
| Q1 2025 | +4.9% | -4.0% | -9.5% | |
| Q4 2024 | -1.5% | +1.2% | +14.7% | |
| Q3 2024 | +5.5% | +5.5% | +21.6% | |
| Q2 2024 | -3.6% | -1.4% | +30.7% | |
| Q1 2024 | -10.9% | -11.4% | -17.5% | |
| Q4 2023 | +5.7% | +9.3% | +1.0% | |
| Q3 2023 | -6.6% | -5.4% | +2.9% | |
| Q2 2023 | -1.0% | +1.7% | -12.2% | |
| Q1 2023 | -18.7% | -17.2% | -4.7% | |
| Q4 2022 | -1.8% | -0.1% | +10.3% | |
| Q3 2022 | +5.1% | +1.2% | +1.7% | |
| Q2 2022 | -6.2% | -0.9% | -11.0% | |
| Q1 2022 | +21.2% | +30.1% | +21.5% | |
| Q4 2021 | +5.4% | +2.3% | -8.2% | |
| Q3 2021 | -16.6% | -8.9% | -13.4% | |
| Q2 2021 | +3.0% | +2.0% | -7.9% | |
| Q1 2021 | +69.8% | +74.1% | +69.0% | |
| Q4 2020 | +1.9% | +2.5% | -15.1% | |
| Q3 2020 | -2.2% | +21.7% | +60.9% | |
| Q2 2020 | +17.3% | +6.4% | -22.4% | |
| Q1 2020 | -0.2% | -1.3% | +82.3% | |
| Q4 2019 | -5.8% | -17.7% | -6.2% | |
| Q3 2019 | -2.6% | -3.6% | +0.9% | |
| Q2 2019 | -1.9% | -1.9% | +0.9% | |
| Q1 2019 | -0.9% | -1.9% | -5.7% | |
| Q4 2018 | +4.2% | +22.4% | -65.0% | |
| Q3 2018 | -1.4% | -11.7% | -2.3% | |
| Q2 2018 | -1.7% | +3.9% | -3.8% | |
| Q4 2011 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro